259 related articles for article (PubMed ID: 16961673)
1. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
Tornvall P; Nilsson T; Lagerqvist B
J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
[TBL] [Abstract][Full Text] [Related]
2. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
3. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
4. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
[TBL] [Abstract][Full Text] [Related]
5. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
[TBL] [Abstract][Full Text] [Related]
6. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
Valgimigli M; Campo G; Arcozzi C; Malagutti P; Carletti R; Ferrari F; Barbieri D; Parrinello G; Percoco G; Ferrari R
J Am Coll Cardiol; 2007 Jul; 50(2):138-45. PubMed ID: 17616297
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
[TBL] [Abstract][Full Text] [Related]
10. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
[TBL] [Abstract][Full Text] [Related]
11. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Legutko J; Mielecki W; Depukat R; Janzon M; Stefaniak J; Zmudka K; Dubiel JS; Partyka L; Dudek D
Am Heart J; 2009 Oct; 158(4):569-75. PubMed ID: 19781416
[TBL] [Abstract][Full Text] [Related]
12. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
[TBL] [Abstract][Full Text] [Related]
14. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
15. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
Cox DA; Stone GW; Grines CL; Stuckey T; Zimetbaum PJ; Tcheng JE; Turco M; Garcia E; Guagliumi G; Iwaoka RS; Mehran R; O'Neill WW; Lansky AJ; Griffin JJ;
Am J Cardiol; 2006 Aug; 98(3):331-7. PubMed ID: 16860018
[TBL] [Abstract][Full Text] [Related]
16. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
[TBL] [Abstract][Full Text] [Related]
17. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
18. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry.
Dudek D; Siudak Z; Janzon M; Birkemeyer R; Aldama-Lopez G; Lettieri C; Janus B; Wisniewski A; Berti S; Olivari Z; Rakowski T; Partyka L; Goedicke J; Zmudka K;
Am Heart J; 2008 Dec; 156(6):1147-54. PubMed ID: 19033011
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
20. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
Huang R; Sacks J; Thai H; Goldman S; Morrison DA; Barbiere C; Ohm J
Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
